01 January 2000
High-dose anthracyclines in the treatment of advanced primitive neuroectodermal tumors in adults - a single institution experience.
Davorin Radosavljević, Svietislav Jelić, Zoran Tomasević, Suzana Matković, Ljiljana Stamatović, Zorica Nikolić-Tomasević, Ivan PopovMed Sci Monit 2000; 6(3): CR512-518 :: ID: 421316
Abstract
Primitive neuroectodermal tumors (PNET) are rare malignancies of presumedneural crest origin, most often presenting as bone or soft tissue masses in the trunk or axial skeleton,in children and young adults. Treatment of advanced PNET in adults is not clearly defined in the literature.Data concerning dose-intensive chemotherapy regimens for poor-risk patients with those tumors are sparse,due to rarity of PNET in adults, their diverse presentation, the variable treatment procedures appliedand the absence of direct comparisons. On the other hand, the role of anthracyclines in the treatmentof advanced soft tissue sarcomas is well known and substantial. Six advanced PNET patients were treatedat the Institute for Oncology and Radiology of Serbia, during last five years, with high-doses of doxorubicinor epidoxorubicin combined with cisplatin. The paper reviews each of our patients, discussing how doeschemotherapy influence the outcome in these patients, in context of the feasibility of high-doses ofanthracyclines in advanced settings. High dose anthracyclines (epidoxorubicin 150 mg/m2) in combinationwith cisplatin 120 mg/m2 induced a complete response lasting for 63+ months in a patient with desmoplasticmedulloblastoma of the cerebellum metastatic to bones and bone marrow. The same treatment but with theepidoxorubicin dose of 180 mg/m2 induced a complete response in a patient with olfactory neuroblastoma.Administration of high dose Doxorubicin (75 mg/m2) seems feasible in association with irradiation treatmentin patients with extraosseal Ewing sarcoma/PNET but the place of high dose chemotherapy within this settingremains to be determined.
Keywords: Antibiotics, Antineoplastic, Cerebellar Neoplasms, Disease-Free Survival, Epirubicin, Medulloblastoma, Neuroblastoma, Neuroectodermal Tumors, Primitive
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
14 Mar 2024 : Clinical Research
Renal Dysfunction Increases Risk of Adverse Cardiovascular Events in 5-Year Follow-Up Study of Intermediate...Med Sci Monit In Press; DOI: 10.12659/MSM.943956
15 Mar 2024 : Clinical Research
Impact of One-Lung Ventilation on Oxygenation and Ventilation Time in Thoracoscopic Heart Surgery: A Compar...Med Sci Monit In Press; DOI: 10.12659/MSM.943089
14 Mar 2024 : Clinical Research
Differential DHA and EPA Levels in Women with Preterm and Term Births: A Tertiary Hospital Study in IndonesiaMed Sci Monit In Press; DOI: 10.12659/MSM.943895
15 Mar 2024 : Clinical Research
Evaluation of an Optimized Workflow for the Radiofrequency Catheter Ablation of Paroxysmal Atrial FibrillationMed Sci Monit In Press; DOI: 10.12659/MSM.943526
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952